Cosciens Biopharma (CSCI) said Thursday it has started the phase 2a clinical efficacy study of its avenanthramides product, which it is developing for potential applications in managing conditions related to inflammation.
In phase 2a of the study, 20 patients with mild to moderate inflammation will participate. This phase is designed to assess potential efficacy in two arms with patients receiving selected doses of 480 mg and 960 mg per day, the company said. Initial dosing is expected to occur on March 14.
The Data Safety and Monitoring Board recommended initiating phase 2a after phase 1, done in November 2023, showed the favorable safety profile of the product, the company said.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。